FindTrial
Sign In

PILOT, OPEN NON COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICAY AND SAFETY OF RETAANE (ANECORTAVE ACETATO 15 MG, 0.5 ML DI 30 MG/ML ANECORTAVE ACETATO STERILE SUSPENSION) IN PATIENTS WITH COROIDEAL NEOVASCULARIZATION FORMS SECONDARY TO SENILE MACULAR DEGENERATION.

PILOT, OPEN NON COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICAY AND SAFETY OF RETAANE (ANECORTAVE ACETATO 15 MG, 0.5 ML DI 30 MG/ML ANECORTAVE ACETATO STERILE SUSPENSION) IN PATIENTS WITH COROIDEAL NEOVASCULARIZATION FORMS SECONDARY TO SENILE MACULAR DEGENERATION.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-001971-36-IT
Enrollment
Unknown
Registered
2005-09-26
Start date
2005-05-25
Completion date
Unknown
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

RETAANE TREATMENT OF COROIDEAL NEOVASCULARIZATION FORMS SECONDARY TO SENILE MACULAR DEGENERATION MedDRA version: 6.1 Level: SOC Classification code 10015919

Interventions

Product Name: anecortave acetato Product Code: NA Pharmaceutical Form: Eye drops, suspension INN or Proposed INN: anecortave acetate CAS Number: NA Current Sponsor code: anecortave acetato (AL-3789) A

Sponsors

OSPEDALE S. RAFFAELE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026